Get access to Glenmark information and resources for stories in development.
Find recent and archived press releases.
Glenmark Pharmaceuticals Reports Positive Results from a Phase 3 Trial of GSP 301, Mometasone/Olopatadine Fixed-Dose Combination Nasal Spray, in Seasonal Allergic Rhinitis
March 29, 2017
March 21, 2017
Search Result :-Is an investigational new drug that has not been approved for commercial distribution in the United States.
US Media Contact
For media inquiries only, please contact An Phan, Corporate Communications.
For more information on Glenmark Pharmaceuticals Ltd., including Annual Reports, Analyst Presentations and Financial Results, please visit our Investor Relations.